Publicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (21)

2019

  1. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

2017

  1. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 10, pp. 2869-2878

  2. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  3. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  4. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

  5. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

  3. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2011

  1. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)

    HIV Medicine, Vol. 12, Núm. 6, pp. 374-382

  2. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial

    Antiviral Therapy, Vol. 16, Núm. 3, pp. 339-348

2010

  1. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study

    The Lancet, Vol. 376, Núm. 9738, pp. 340-345

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

  2. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

  3. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal

    Clinical Infectious Diseases, Vol. 48, Núm. 8, pp. 1138-1151

2007

  1. Infection by the type 2 human immunodeficiency virus and types 1 and 2 human lymphotropic virus in Spain

    Medicina Clinica

2006

  1. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: Results from a large multicenter observational cohort

    Journal of Acquired Immune Deficiency Syndromes, Vol. 41, Núm. 2, pp. 154-159

  2. Tratamiento antirretroviral según tipos y subtipos del virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. SUPPL.2, pp. 29-33